FOXD1 and prostate carcinoma: In prostate cancer, cervical cancer, and colorectal cancer, FOXD1 is markedly up-regulated and indicates a poor prognosis of the patients; functionally, FOXD1 can promote tumor growth and metastasis [38–41].